CureMatch, a digital health company focusing on personalized medicine and combination therapy in oncology, is Serra Capital III's 13th investment. Serra is participating in the company's Bridge to Series A round.
"CureMatch represents a unique, breakthrough opportunity in the treatment of cancer, a disease that touches all of our lives in some way," said Steve Beck, Managing Partner at Serra Venture's San Diego office. "The company's solution resides at the intersection of precision medicine and actionable intelligence extracted from big data. We're confident that the CureMatch team is poised to lead the way in personalized cancer treatment, and we are thrilled to add them to the Serra Ventures' portfolio."